** Shares of Ion Beam Applications IBAB.BR rise more than 5% after the radiopharmaceuticals equipment company said it had won a contract for its proton therapy system ProteusPlus in South Korea
** IBA says contracts for ProteusPlus, which is used to treat cancer, typically range from 80 million euros to 100 million euros ($94.1 million-$117.7 million)
** "This is the first P+ contract outside China since 2016," says Michiel Declercq, analyst at KBC Securities
** The contract reconfirms IBA's pricing power and further strengthens its backlog, Declercq says
** Shares in IBA trade at 12.8 euros at 0832 GMT, their highest since March 20
($1 = 0.8494 euros)